Predictive value of interim 18F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
Identificadores
Identificadores
Fecha de publicación
2013Título de revista
NUCLEAR MEDICINE COMMUNICATIONS
Tipo de contenido
Artigo